The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe
The notion that targeted drugs can unplug gain-of-function tumor pathways has revitalized pharmaceutical research, but the survival benefits of this strategy have so far proven modest. A weakness of oncogene-blocking approaches is that they do not address the problem of cancer progression as selecte...
Main Author: | Richard J. Epstein |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2013-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00304/full |
Similar Items
-
Effect of ionizing radiation at low dose on transgenerational carcinogenesis by epigenetic regulation
by: Lan Li, et al.
Published: (2017-12-01) -
WWOX Tumor Suppressor Gene in Breast Cancer, a Historical Perspective and Future Directions
by: Karolina Pospiech, et al.
Published: (2018-08-01) -
The quest for targets executing MYC-dependent cell transformation
by: Markus eHartl
Published: (2016-06-01) -
Oncogenic and tumor suppressive roles of special AT-rich sequence-binding protein
by: Qiao Yi Chen, et al.
Published: (2018-01-01) -
Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Functions
by: Sachiko Matsuhashi, et al.
Published: (2019-05-01)